Sequencing


nor industry have completely settled on a single approach to the use and validation of NGS-sourced data. The questions for those involved in the regu- lated domains of drug and diagnostic development then become: where to begin and which technolo- gies, standards and initiatives are worth following? It may be neither possible nor desirable to devel- op a single, standard approach that works for all of the ways that NGS data can be applied in clini- cal development and practice, but that should not stop the industry from developing best practices that can serve as a template for practitioners (while recognising and adapting to the reality of fast-mov- ing technological change). Pre-competitive consor- tia such as the Pistoia Alliance can serve to bring together stakeholders from the pharma and diag- nostic industries, the technology service providers and the regulators, to share experience and to develop those best practices in real-world develop- ment. In this way the industry can work with the regulators to develop appropriate approaches to the use and validation of these new technologies


and avoid each company individually having to learn the same lessons on its own.


DDW


Keith Nangle was formerly Head of Genetic Data Sciences at GlaxoSmithKline Inc. He also served as European Community Manager for the tranSMART Foundation before working with the Pistoia Alliance on the use of NGS in regulated areas of drug development.


Mike Furness is Founder and MD of TheFirstNuomics and has worked in genomics and bioinformatics for the last 30 years providing expert technical and business development sup- port to a range of start-up companies and investors. He has previously worked at Congenica, DNAnexus, Incyte Genomics, Pfizer, Cancer Research UK and Life Technologies, and is working with the Pistoia Alliance on its Companion Diagnostics NGS project.


Advanced Cell Diagnostics Agilent Technologies, Inc Biostrata Ltd


BioTek Instruments, Inc BMG Labtech GmbH


Charles River Laboratories, Inc Chemspec Europe


9,15


39,47 38 20 24 48 67


ADVERTISEMENT INDEX 3


Corning, Inc Essen Bioscience, Inc


Eurofins Pharma Discovery Services IntelliCyt Corporation Labcyte, Inc


Miltenyi Biotec GmbH PerkinElmer, Inc


40 6


32 16 35


OBC


Quanterix Corporation Select Biosciences Ltd SLAS


Source Bioscience Unchained Labs


IFC IBC 53 4


23


70


Drug Discovery World Winter 2017/18


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72